ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Omega-3 pretreatment attenuates hepatic inflammatory histopathology in LPS-Induced rat endotoxemia: exploratory SIRT1/HO-1 findings.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a major global contributor to morbidity and mortality, and liver dysfunction intensifies disease severity. Lipopolysaccharide (LPS)-induced liver injury is characterized by inflammation, oxidative stress, and apoptosis, whereas the sirtuin-1 (SIRT1) and nuclear factor erythroid 2-related factor 2 (NRF2)/heme oxygenase-1 (HO-1) pathway provides essential cellular protection. Although omega-3 (OMG3) polyunsaturated fatty acids are recognized for their anti-inflammatory and antioxidant properties, their effects on this pathway remain unclear. This study investigated the hepatoprotective effects of OMG3 pretreatment against LPS-induced hepatic injury in rats, evaluating histopathological injury as the primary endpoint together with hepatic SIRT1, NRF2, and HO-1 expression, inflammatory/apoptotic markers, and redox status as secondary/exploratory outcomes. Thirty-two female Wistar Albino rats were assigned to four groups: control, LPS (5 mg/kg, i.p.), LPS + OMG3, and OMG3 (0.5 g/kg/day, i.p.). Liver tissues were analyzed by histopathology, immunohistochemistry, RT-qPCR, and oxidative stress assays, including total antioxidant status (TAS), total oxidant status (TOS), and oxidative stress index (OSI). LPS produced significant histopathological damage (hemorrhage, inflammation, and necrosis scores; all p ≤ 0.003 vs. control), increased immunoreactivity of Caspase-3, NF-κB, TNF-α, and VEGF (all p ≤ 0.005), decreased hepatic SIRT1 and HO-1 mRNA expression (p = 0.015, p = 0.009), and elevated OSI (p < 0.001). Three-day OMG3 pretreatment significantly reduced the histopathological inflammation score versus LPS (adjusted p = 0.037); reductions in hemorrhage and necrosis scores, Caspase-3/NF-κB/TNF-α/VEGF immunoreactivity, SIRT1/HO-1 mRNA expression, and TAS/OSI were directionally favorable but did not reach significance (adjusted p = 0.050-0.763). NRF2 expression and TOS did not differ among groups. Under this prophylactic regimen, 3-day OMG3 pretreatment significantly attenuated the histopathological inflammatory response to acute LPS-induced hepatic injury. Reductions in apoptotic, inflammatory, and angiogenic immunoreactivity, hepatic SIRT1/HO-1 expression, and redox indices were directionally consistent but statistically unconfirmed in the LPS + OMG3-versus-LPS comparison, and should be interpreted as exploratory. Activation of the SIRT1-NRF2/HO-1 pathway was not established at the protein level, and further dose-ranging and mechanistic studies are needed before extrapolating these findings to a therapeutic context.
Indexed as
Identifiers
42839045What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.